Infante JR, Braiteh F, Emens L, Balmanoukian AS, Oaknin A, Wang Y, et al. Safety, clinical activity and biomarkers of atezo-lizumab (atezo) in advanced ovarian cancer (OC). Ann Oncol. 2016;27:871. 2. Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL. Immunity and immune suppression in human ovarian cancer.Immunotherapy. 2011;3:539 –56.